OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
February 23, 2017
The industry is becoming more consolidated, but there needs to be some strategy behind the mergers and acquisitions.
February 17, 2017
SGS expands its elemental impurity testing services at its laboratory in Villeneuve-la-Garenne, France.
February 14, 2017
Quotient Clinical’s addition of CDMO QS Pharma increases the company’s footprint in the US an adds high potency molecule capability.
February 02, 2017
The outlook for the CMO and CDMO industry may be affected by ever-changing politics.
February 01, 2017
Analytical products for improved bio/pharmaceutical development.
Cold-chain requirements and the tight logistical windows needed for cell and gene therapies demand a focus on early communication and risk mitigation.
Andrea Zobel, senior director of product management, clinical trial supply, and logistics at PAREXEL International, examines key issues and questions that sponsors and contract partners must address.
Many pharmaceutical manufacturers were late in involving contract partners in serialization efforts. Are you ready, and are you working with the right partner?
As the date for implementation of the Drug Supply Chain Security Act approaches, bio/pharma companies and contractors should focus on key areas.
Selecting the best partner contract service and fostering a successful relationship requires detailed research and effective communication.